Cosmo N.V.

0RGI.L

Medical - Pharmaceuticals · Healthcare

Price

63.20 GBp

-0.07 (-0.11%)

Market Cap

£1.02B

Exchange

London Stock Exchange

Winston Score

Winston is curious

A decent business — some strong pillars, some weaker.

Share count falling — buybacks

−5.5% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 16.9M (2021) → 16.0M (2025)

Cosmo Pharmaceuticals is a specialty drug company that focuses on medicines for the digestive system, particularly the colon and intestines. Its best-known product is Methylene Blue MMX, a dye used during colonoscopies to help doctors spot abnormal tissue more easily. The company also develops drug-device combinations and has licensed several products to larger pharmaceutical partners.

Cosmo makes money through a mix of product sales, royalties, and licensing deals with bigger drugmakers who sell Cosmo's products in various markets. It operates primarily in Europe and North America, and its main edge comes from patented drug-delivery technology that controls how and where a medicine is released in the gut. The company is currently unprofitable at the operating level, and its growth depends heavily on whether its pipeline products gain regulatory approval and whether licensing partners successfully commercialize the drugs they have licensed from Cosmo.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-59.8% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-102.9% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$32M/ year

↓ Declining (-19% vs prior year)

30.8% of revenue

1.7x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

46.3%ownership

↓ Declining

Insider ownership declining — could be dilution or selling

Cash Runway

~12 months

$56M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Adequate runway but may need to raise capital within 2 years

Revenue declining

Cosmo N.V.'s revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

46.5%

Healthy — 46.5% gross margin

Operating Margin

-8.2%

Losing money on operations — -8.2%

ROCE

-0.9%

Weak — -0.9% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+90.4%

Fast-growing sales (90.4% YoY)

EPS YoY

+953.2%

Earnings growing fast (953.2% YoY)

Earnings growing 25%+ a year. The compounder zone.

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

116%

Turns 116% of profit into real cash

FCF Margin

38.2%

Converts sales into free cash efficiently (38.2%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.00

Conservative — low debt load (0.00)

Interest Cover

1722.03x

Comfortably covers interest (1722.0x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

8.0x

Attractive valuation — P/E 8.0

P/E under 10. The price tag is small relative to last year's profit.

P/E vs Forward

-10.9

SLOWING

Earnings expected to fall — forward P/E higher than today

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield

2.74%

Moderate income — 2.74% yield

Standard yield zone for stable dividend payers. A meaningful piece of total return.

Dividend Growth

N/A

no trend

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial